ATE71303T1 - Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. - Google Patents
Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.Info
- Publication number
- ATE71303T1 ATE71303T1 AT87200035T AT87200035T ATE71303T1 AT E71303 T1 ATE71303 T1 AT E71303T1 AT 87200035 T AT87200035 T AT 87200035T AT 87200035 T AT87200035 T AT 87200035T AT E71303 T1 ATE71303 T1 AT E71303T1
- Authority
- AT
- Austria
- Prior art keywords
- immunogenic
- preparation
- pharmaceutical composition
- composition containing
- detergent
- Prior art date
Links
- 230000001900 immune effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 4
- 229930182558 Sterol Natural products 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000003599 detergent Substances 0.000 abstract 2
- 229930182470 glycoside Natural products 0.000 abstract 2
- 150000002338 glycosides Chemical class 0.000 abstract 2
- 239000000693 micelle Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 150000003432 sterols Chemical class 0.000 abstract 2
- 235000003702 sterols Nutrition 0.000 abstract 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 abstract 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8600066 | 1986-01-14 | ||
| EP87200035A EP0231039B1 (de) | 1986-01-14 | 1987-01-13 | Verfahren zur Herstellung immunologischer Komplexe und diese enthaltende pharmazeutische Zusammensetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE71303T1 true ATE71303T1 (de) | 1992-01-15 |
Family
ID=19847414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT87200035T ATE71303T1 (de) | 1986-01-14 | 1987-01-13 | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4900549A (de) |
| EP (1) | EP0231039B1 (de) |
| JP (2) | JP2502558B2 (de) |
| AT (1) | ATE71303T1 (de) |
| CA (1) | CA1279012C (de) |
| DE (1) | DE3775783D1 (de) |
| DK (1) | DK166762B1 (de) |
| ES (1) | ES2039229T3 (de) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| ES2039229T3 (es) * | 1986-01-14 | 1993-09-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos. |
| US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
| ZA888577B (en) * | 1987-11-27 | 1989-08-30 | Akzo Nv | Stabilization of antibodies |
| US6291228B1 (en) | 1988-08-03 | 2001-09-18 | Vericore Limited | Vaccine |
| NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| GB8919819D0 (en) * | 1989-09-01 | 1989-10-18 | Coopers Animal Health | Complexes having adjuvant activity |
| US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| US5443832A (en) * | 1990-04-16 | 1995-08-22 | Institut Swisse De Recherches Experimentales Sur Le Cancer | Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response |
| NL9002314A (nl) * | 1990-10-23 | 1992-05-18 | Nederlanden Staat | Immunogene complexen, in het bijzonder iscoms. |
| SE502569C2 (sv) * | 1991-05-31 | 1995-11-13 | British Tech Group | Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit |
| WO1993020802A1 (en) * | 1992-04-09 | 1993-10-28 | Northwestern University | Acoustically reflective liposomes and methods to make and use the same |
| DE4220653A1 (de) * | 1992-06-26 | 1994-01-13 | Boehringer Mannheim Gmbh | Verfahren und Mittel zum Nachweis eines Analyten enthaltend glykosidische Tenside |
| AU677826B2 (en) * | 1993-02-26 | 1997-05-08 | Fountain Pharmaceuticals, Inc. | Vaccine delivery system and shelf-stable precursor solution for remote encapsulation of active ingredients |
| AUPM500494A0 (en) * | 1994-04-12 | 1994-05-05 | Minister For Agriculture & Rural Affairs For The State Of New South Wales, The | Composition for use in increasing mucosal immunity |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| GB9618119D0 (en) | 1996-08-30 | 1996-10-09 | Univ Southampton | Adjuvants for use in vaccines |
| US6455323B1 (en) | 1997-07-03 | 2002-09-24 | Pharmacia & Upjohn Company | Anti-bacterial methods and materials |
| US20070059327A2 (en) * | 1998-01-15 | 2007-03-15 | Wyeth | Streptococcus equi compositions and methods of use |
| GB2348203B (en) | 1998-11-04 | 2002-06-19 | Imp College Innovations Ltd | Solube beta-forms of prion proteins, methods of preparation and use |
| AUPP807399A0 (en) * | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| DE60044236D1 (de) | 1999-02-17 | 2010-06-02 | Csl Ltd | Immunogene komplexe und methoden in bezug auf diese |
| US6790950B2 (en) | 1999-04-09 | 2004-09-14 | Pharmacia & Upjohn Company | Anti-bacterial vaccine compositions |
| KR20060116041A (ko) | 1999-04-09 | 2006-11-13 | 파마시아 앤드 업존 캄파니 엘엘씨 | 항균성 백신 조성물 |
| BR0109322A (pt) | 2000-03-17 | 2002-12-10 | Upjohn Co | Materiais e métodos de vacina de salmonella |
| WO2001077365A2 (en) | 2000-04-06 | 2001-10-18 | Pharmacia & Upjohn Company | Antimicrobial methods and materials |
| US7323174B1 (en) | 2000-06-12 | 2008-01-29 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Modulation of immune response and methods based thereon |
| CU23002A1 (es) * | 2000-12-01 | 2004-11-18 | Ct Ingenieria Genetica Biotech | Método de obtención de agregados antigénicos y su uso en formulaciones |
| CA2327950A1 (en) * | 2000-12-08 | 2002-06-08 | Groupe Minutia Inc. | Grain refining agent for cast aluminum or magnesium products |
| US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| GB0112126D0 (en) | 2001-05-18 | 2001-07-11 | Allergene Inc | Composition |
| IL145926A0 (en) | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
| US6861410B1 (en) * | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
| SE0202110D0 (sv) * | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| US7491395B2 (en) | 2002-11-20 | 2009-02-17 | Bestewil Holding B.V. | Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination |
| WO2004045641A2 (en) | 2002-11-20 | 2004-06-03 | Crucell Holland B.V. | Antigen-complexes |
| IL155136A0 (en) | 2003-02-10 | 2003-10-31 | Enzymotec Ltd | A composition for reducing blood cholesterol and triglycerides |
| US20060233863A1 (en) | 2003-02-10 | 2006-10-19 | Enzymotec Ltd. | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy |
| EP1447080A1 (de) * | 2003-02-13 | 2004-08-18 | Bestewil Holding B.V. | Methode zur Herstellung von Virosomen-artigen Partikeln |
| SE0300795D0 (sv) * | 2003-03-24 | 2003-03-24 | Isconova Ab | Composition comprising iscom particles and live micro-organisms |
| TWI329130B (en) | 2003-06-19 | 2010-08-21 | Bestewil Holding Bv | Functionally reconstituted viral membranes containing adjuvant |
| US9023366B2 (en) | 2003-07-01 | 2015-05-05 | The Royal Veterinary College | Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD) |
| GB0315323D0 (en) | 2003-07-01 | 2003-08-06 | Royal Veterinary College | Vaccine composition |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| JP2008506789A (ja) | 2004-07-18 | 2008-03-06 | シーエスエル、リミテッド | インターフェロン−ガンマ応答強化を誘発するための免疫刺激複合体及びオリゴヌクレオチド処方物 |
| US20090232916A1 (en) * | 2004-08-09 | 2009-09-17 | Avidor Shulman | Food products for diabetics |
| AU2005270831B2 (en) | 2004-08-10 | 2011-08-25 | Enzymotec Ltd. | Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions |
| ES2433467T3 (es) * | 2005-01-20 | 2013-12-11 | Isconova Ab | Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina |
| ATE516817T1 (de) | 2005-06-16 | 2011-08-15 | Univ Gent | Impfstoffe zur immunisierung gegen helicobacter |
| WO2007000768A2 (en) * | 2005-06-28 | 2007-01-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Gliomedin, fragments thereof and methods of using same |
| EP1912665B1 (de) | 2005-07-28 | 2011-01-26 | Pfizer Products Inc. | Impfstoff gegen felines calicivirus (fcv), der ein fcv kapsid protein oder ein isoliertes fcv kapsid protein mit der protein sequenz seq id no: 13 oder mit einer protein sequenz, die zumindestens zu 95% identisch zur seq id no: 13 ist enthält. |
| EP1764369A1 (de) | 2005-09-16 | 2007-03-21 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants |
| WO2007042884A1 (en) | 2005-10-07 | 2007-04-19 | Pfizer Products Inc. | Vaccines and methods to treat canine influenza |
| ES2951660T3 (es) | 2006-12-27 | 2023-10-24 | Zoetis Services Llc | Procedimientos de administración de vacunas |
| WO2008142693A2 (en) * | 2007-05-22 | 2008-11-27 | Yeda Research And Development Co. Ltd. | Regulation of myelination by nectin-like (necl) molecules |
| JP2010038051A (ja) | 2008-08-06 | 2010-02-18 | Denso Corp | 車載動力発生装置のトルク制御装置 |
| US8623375B2 (en) | 2010-05-14 | 2014-01-07 | Baxter International Inc. | Chimeric OspA genes, proteins, and methods of use thereof |
| KR101924653B1 (ko) * | 2010-06-24 | 2018-12-03 | 제넨테크, 인크. | 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법 |
| WO2012010290A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| WO2012010291A1 (en) | 2010-07-21 | 2012-01-26 | Athera Biotechnologies Ab | Diagnostic and therapeutic methods and compositions for metabolic disease |
| WO2012059592A1 (en) | 2010-11-05 | 2012-05-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compounds for delivering a therapeutic or imaging agent to the brain |
| EP2462950A1 (de) | 2010-12-08 | 2012-06-13 | Neovacs | Stark inaktivierter und weiterhin hoch immunogener Impfstoff, sowie Verfahren zu seiner Herstellung |
| EP2648746A1 (de) | 2010-12-08 | 2013-10-16 | Neovacs | Stark inaktivierter und weiterhin hoch immunogener impfstoff sowie verfahren zu seiner herstellung |
| WO2012131099A1 (en) | 2011-03-31 | 2012-10-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications |
| CA2832260C (en) | 2011-04-07 | 2021-06-22 | Neovacs | Method for treating ifnalpha related conditions |
| EP2508197A1 (de) | 2011-04-07 | 2012-10-10 | Neovacs | Verfahren zur Behandlung IFN-alpha-assoziierter Erkrankungen |
| DK2750683T4 (da) * | 2011-10-03 | 2021-04-12 | Croda Int Plc | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser |
| GB201200259D0 (en) | 2012-01-09 | 2012-02-22 | Ohlin Per M | Novel therapies |
| WO2014018274A1 (en) | 2012-07-27 | 2014-01-30 | Baxter International, Inc. | Compositions comprising chimeric ospa molecules and methods of use thereof |
| EP2949339A1 (de) | 2014-05-29 | 2015-12-02 | Ospedale San Raffaele S.r.l. | Agonisten von CD1c-abhängigen T Zellen und Verwendungen davon |
| CN121021679A (zh) | 2014-10-15 | 2025-11-28 | 芝诺锡拉公司 | 具有降低的免疫原性的组合物 |
| CN114617959A (zh) | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
| CN111148509A (zh) | 2017-07-24 | 2020-05-12 | 诺瓦瓦克斯股份有限公司 | 治疗呼吸系统疾病的方法和组合物 |
| CN120227451A (zh) | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| AU2021214064A1 (en) | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| EP3922255A1 (de) | 2020-06-10 | 2021-12-15 | Prokarium Limited | Krebstherapie |
| EP4124342A1 (de) | 2021-07-28 | 2023-02-01 | Prokarium Limited | Krebstherapie mit lebenden attenuierten bakterien |
| GB2622559A (en) | 2022-05-10 | 2024-03-27 | Johan Frostegaard | Compositions, methods and uses |
| GB202215134D0 (en) | 2022-10-13 | 2022-11-30 | Prokarium Ltd | Composition |
| GB202215576D0 (en) | 2022-10-21 | 2022-12-07 | Prokarium Ltd | Circuit |
| WO2025068401A1 (en) | 2023-09-28 | 2025-04-03 | Prokarium Limited | Interleukin 15 variant |
| WO2025068413A1 (en) | 2023-09-28 | 2025-04-03 | Prokarium Limited | Interleukin 18 variants |
| WO2025109155A1 (en) | 2023-11-24 | 2025-05-30 | Prokarium Limited | Interleukin variant |
| KR20250155284A (ko) * | 2024-04-23 | 2025-10-30 | (주)아모레퍼시픽 | 미셀을 이용한 유효성분의 봉입 및 안정성 개선 방법 |
| WO2025224251A1 (en) | 2024-04-24 | 2025-10-30 | Prokarium Limited | Modified microorganisms |
| GB202405780D0 (en) | 2024-04-24 | 2024-06-05 | Prokarium Ltd | Vacuole escape |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1502774A (en) * | 1974-06-25 | 1978-03-01 | Nat Res Dev | Immunological preparations |
| US4196191A (en) * | 1975-09-29 | 1980-04-01 | Burroughs Wellcome Co. | Biological preparations |
| US4201767A (en) * | 1978-11-08 | 1980-05-06 | Merck & Co., Inc. | Viral liposome particle |
| AU534679B2 (en) * | 1979-03-15 | 1984-02-09 | Commonwealth Scientific And Industrial Research Organisation | Steroid immunogens |
| DE3068743D1 (en) * | 1980-01-16 | 1984-08-30 | Weder Hans G | Process and dialysis-installation for the preparation of bilayer-vesicles and their use |
| US4439199A (en) * | 1980-02-19 | 1984-03-27 | Alza Corporation | Method for administering immunopotentiator |
| DE3014189A1 (de) * | 1980-04-14 | 1981-10-15 | Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg | Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren |
| DE3173713D1 (en) * | 1980-09-05 | 1986-03-20 | Frappier Armand Inst | Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane |
| US4386066A (en) * | 1981-08-20 | 1983-05-31 | Merck & Co., Inc. | Immunogenic complex from N. gonorrhoeae |
| SE8205892D0 (sv) * | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| EP0142193A1 (de) * | 1983-10-22 | 1985-05-22 | Akzo N.V. | Herstellung von Immunogenen bestehend aus an Glykosid enthaltenden Trägern gebundenen Antigenen und/oder antigenen Determinanten |
| SE8405493D0 (sv) * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
| ES2039229T3 (es) * | 1986-01-14 | 1993-09-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos. |
| US4806350A (en) * | 1986-04-18 | 1989-02-21 | Norden Laboratories, Inc. | Vaccine formulation |
-
1987
- 1987-01-13 ES ES198787200035T patent/ES2039229T3/es not_active Expired - Lifetime
- 1987-01-13 DK DK015087A patent/DK166762B1/da not_active IP Right Cessation
- 1987-01-13 EP EP87200035A patent/EP0231039B1/de not_active Expired - Lifetime
- 1987-01-13 AT AT87200035T patent/ATE71303T1/de not_active IP Right Cessation
- 1987-01-13 DE DE8787200035T patent/DE3775783D1/de not_active Expired - Lifetime
- 1987-01-14 US US07/003,070 patent/US4900549A/en not_active Expired - Lifetime
- 1987-01-14 CA CA000527289A patent/CA1279012C/en not_active Expired - Lifetime
- 1987-01-14 JP JP62007384A patent/JP2502558B2/ja not_active Expired - Lifetime
-
1995
- 1995-11-28 JP JP7309056A patent/JP2703528B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2039229T3 (es) | 1993-09-16 |
| JP2502558B2 (ja) | 1996-05-29 |
| DE3775783D1 (de) | 1992-02-20 |
| DK15087A (da) | 1987-07-15 |
| CA1279012C (en) | 1991-01-15 |
| US4900549A (en) | 1990-02-13 |
| JP2703528B2 (ja) | 1998-01-26 |
| EP0231039B1 (de) | 1992-01-08 |
| EP0231039A1 (de) | 1987-08-05 |
| DK15087D0 (da) | 1987-01-13 |
| DK166762B1 (da) | 1993-07-12 |
| JPS632933A (ja) | 1988-01-07 |
| JPH08208513A (ja) | 1996-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3775783D1 (de) | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. | |
| SE8205892D0 (sv) | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin | |
| DE68921389T2 (de) | Influenzaimpfstoff und Adjuvanten. | |
| DE69010574T2 (de) | Hilfsmittelformulierung die eine Emulsion mit submikronischen Oeltropfen enthält. | |
| KR940001373B1 (ko) | 인플루엔자 백신의 제조방법 | |
| CA2086831C (en) | Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them | |
| AU632067B2 (en) | Matrix with immunomodulating activity | |
| DE69131709T2 (de) | Liposomen enthaltende impfstoffzusammensetzungen | |
| US5147859A (en) | Complexes of glycerrhetinic acid with phospholipids and pharmaceutical and cosmetic compositions containing them | |
| JP2002522397A (ja) | 他の界面活性剤を含有しない、ステロールとサポニンから成るｉｓｃｏｍを含むワクチン | |
| HUT52943A (en) | Process for producing liposome compositions | |
| RO119068B1 (ro) | Compoziţie de vaccin conţinând o saponină şi un sterol | |
| US4148876A (en) | Biological preparations | |
| ZA834998B (en) | Liquid active ingredient concentrates for preparation of microemulsions | |
| KR950700083A (ko) | 경구용 백신(oral vaccine) | |
| EP0478715A4 (en) | Targeted liposomes and methods for liposome-protein coupling | |
| DE68919173T2 (de) | Affinitätsassoziierter Impfstoff. | |
| GB1564500A (en) | Biological preparations | |
| DE69505236T2 (de) | Liposomen und deren verwendung insbesondere zur herstellung immunomodulatorischer mittel | |
| AU9169798A (en) | Antigen vectors in the form of multilamellar vesicles | |
| KR0173365B1 (ko) | C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀 | |
| Freitas et al. | The Use of Liposomes as Snake Venom Vehicles. Application in Protective Immunization | |
| DE69710476T2 (de) | Alkaloidglykoside zur verwendung als arzneimittel | |
| KR0178422B1 (ko) | 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀 | |
| KR0173366B1 (ko) | B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |